Product Description
VERU-944 is being developed by Veru for the treatment of patients with Prostate Cancer Metastatic. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03646162?term=VERU-944&draw=2&rank=1)
Mechanisms of Action: ER Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Veru
Company Location: MIAMI FL 33127
Company CEO: Mitchell S. Steiner
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03646162 |
V72203 | P2 |
Completed |
Prostate Cancer |
2020-04-30 |
12% |
2021-06-19 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/04/2019 |
News Article |
Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA |
|
05/28/2019 |
News Article |
Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th |
|
05/08/2019 |
News Article |
Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th |
|
03/12/2019 |
News Article |
Veru to Participate in Two Investor Conferences in March |